Drugs / Allogeneic CD56-positive CD3-negative Natural Killer Cells
Allogeneic CD56-positive CD3-negative Natural Killer Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01823198 | Jun 2013 → May 2022 | acute erythroid leukemia, acute megakaryoblastic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, chronic myelomonocytic leukemia +2 | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic CD56-positive CD3-negative Natural Killer Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01823198 ↗ |
| Modality | Cell therapy | “allogeneic CD56-positive CD3-negative natural killer cells” NCT01823198 ↗ |
| Route | Intravenous | “Given IV” NCT01823198 ↗ |